ArticlePloS one2022
Breast cancer incidence and predictions (Monastir, Tunisia: 2002-2030): A registry-based study.
Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Epidemiology and Clinical Features of Breast Cancer in Cotonou (2014-2019): Insights from a Population-Based Registry Study.Annals of surgical oncology · 2026Article
- Survival and disease burden of breast cancer (Monastir, Tunisia): A population-based cohort study (2002-2022).PloS one · 2026Article
- Female breast cancer burden among adolescent and young adults in North Africa.Breast cancer (Tokyo, Japan) · 2025Article
- A Descriptive Phenomenological Study of the Women's Experiences From the Suspicion of Breast Cancer to the Initiation of Treatment.Scandinavian journal of caring sciences · 2025Article
- The effect of the COVID-19 pandemic on clinical and pathologic stages of patients diagnosed with breast cancer.Irish journal of medical science · 2025Article
- Incidence and survival of Lung Cancer: A retrospective population-based cohort (Monastir, Tunisia: 2002-2022).PloS one · 2025Article
- Estimated Cancer Incidence in Northern Tunisia in 2023: Northern Tunisia Cancer Registry.Asian Pacific journal of cancer prevention : APJCP · 2024Article
- Involvement ofFrontiers in cell and developmental biology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionBreast cancer is a major public health problem worldwide. It is the leading cause of cancer deaths in females. In developing countries like Tunisia, the frequency of this cancer is still growing. The aim of this study was to determine the crude and standardized incidence rates, trends and predictions until 2030 of breast cancer incidence rates in a Tunisian governorate.
methodsThis is a descriptive study including all female patients diagnosed with breast cancer in Monastir between 2002 and 2013. The data were collected from the cancer register of the center. Tumors were coded according to the 10th version of international classification of disease (ICD-10). Trends and predictions until 2030 were calculated using Poisson linear regression.
resultsA total of 1028 cases of female breast cancer were recorded. The median age of patients was 49 years (IQR: 41-59 years) with a minimum of 16 years and a maximum of 93 years. The age-standardized incidence rate (ASR) was of 39.12 per 100000 inhabitants. It increased significantly between 2002 and 2013 with APC of 8.4% (95% CI: 4.9; 11.9). Prediction until 2030 showed that ASR would reach 108.77 (95% CI: 57.13-209.10) per 100000 inhabitants.
conclusionThe incidence and the chronological trends of breast cancer highlighted that this disease is of a serious concern in Tunisia. Strengthening preventive measures is a primary step to restrain its burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.